We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AdvaMed said the draft guidance was too general in parts and that the FDA should clarify that product centers have responsibility and authority for product-specific premarket decisions. Read More
The agency cited new regulatory challenges, counterfeit or contaminated products and an increased volume of imported products as reasons for the increased fees. Read More